Last month HLS delivered a solid report including a 190% increase in net profit and for the 1st 6-months of 2021 over $950m of revenue, up 16% year on year. Obviously the companies enjoyed a COVID generated surge in revenue through its pathology department but we believe some of this will be maintained as the world moves to a new norm post the pandemic. This is a business we believe is stronger following the sale of its medical and dental centres and although the takeover potential has reduced as the stock rallies we like its outlook moving forward.
scroll
Question asked
Question asked
Question asked
Question asked
Question asked
Question asked
Performance update for March, stocks that drove returns & our current positioning
Close
Friday 26th April – ASX200 -101pts, Newmont (NEM), Resmed (RMD) & Super Retail (SUL)
Close
Market Matters Research Lead Shawn Hickman with David Koch
Close
MM likes HLS moving through 2021.
Add To Hit List
Related Q&A
Thoughts please on HLS & MCR after bids
Thoughts on – CAJ, HLS & ING please?
Does MM like healthcare stocks HLS & CAJ?
Picking a healthcare winner
Technical thoughts on CGF & HLS
Q’s on CSR, BLD, TAH, HLS
Relevant suggested news and content from the site
Video
WATCH
Performance update for March, stocks that drove returns & our current positioning
Recorded Tuesday 9th April
Podcast
LISTEN
Friday 26th April – ASX200 -101pts, Newmont (NEM), Resmed (RMD) & Super Retail (SUL)
Daily Podcast Direct from the Desk
Video
WATCH
Market Matters Research Lead Shawn Hickman with David Koch
Recorded Monday 25th March
Members only
UNLOCK MARKET MATTERS NOW
Take a free trial.
No payment details required.